secwatch.observer — SEC 8-K summary
======================================

Issuer:     MapLight Therapeutics, Inc. (MPLT)
CIK:        0001770069
Form:       8-K
Filed at:   2025-12-04T23:59:59+00:00
Accession:  0001193125-25-307450
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MapLight reports Q3 net loss $29.4M; cash runway through 2027; Phase 2 readouts in 2026-2027
--------------------------------------------------------------------------------

- Net loss $29.4M vs $19.0M in Q3 2024; R&D spend $27.1M (up 61% YoY) on clinical trial costs.
- Cash & investments $227.2M at Q3 end; Oct IPO netted $269.8M, extending runway through 2027.
- Phase 2 ZEPHYR (schizophrenia, n=300) topline H2 2026; VISTA (Alzheimer's psychosis) topline H2 2027.
- ML-004 (autism) IRIS Phase 2 enrollment completed (~160 pts); topline results H2 2026.
- ML-021 (Parkinson's) IND-enabling studies H2 2026; ML-009 (GPR52 PAM) candidate nominated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/0001193125-25-307450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-20251204.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-307450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer